Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etalocib SCHEMBL29379752 | 0.89 | LTB4R (1.00) | LTB4RLTB4R2 | |
| Etalocib SCHEMBL1649516 | 0.89 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9075395 | 0.88 | LTB4R (1.00) | LTB4RLTB4R2 | |
| Etalocib SCHEMBL4306319 | 0.88 | LTB4R (0.98) | LTB4RLTB4R2 | |
| Etalocib SCHEMBL6356831 | 0.88 | LTB4R (0.98) | LTB4RLTB4R2 | |
| SCHEMBL6895091 | 0.87 | LTB4R (0.98) | LTB4RLTB4R2 | |
| SCHEMBL6898153 | 0.87 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL6899046 | 0.86 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7748615 | 0.84 | LTB4R (0.82) | LTB4RLTB4R2 | |
| SCHEMBL9076176 | 0.84 | LTB4R (1.00) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2017-11-23 | — | — | US | claimed |
| US-10849954-B2 | Preventive or therapeutic agent for age-related macular degeneration | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849954-B2 | Preventive or therapeutic agent for age-related macular degeneration | LTB4R, LTA4H, LTB4R2 | LTB4R 1/4885LTB4R2 3/4885 |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | LTB4R, LTA4H, LTB4R2 | LTB4R 1/4885LTB4R2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.